Interim report for the period May 2013 - January 2014

Continued development of the pre-clinical and clinical research program

        Print
| Source: Oasmia Pharmaceutical AB
multilang-release

Uppsala, Sweden, 2014-03-06 08:58 CET (GLOBE NEWSWIRE) --  

THIRD QUARTER November 1, 2013 – January 31, 2014

  • Consolidated Net sales amounted to 2 thousand (0) [1]
  • Operating income amounted to - 3,221 thousand (-1,628)
  • Net income after tax amounted to - 3,440 thousand (-1,757)
  • Earnings per share amounted to - 0.04 (-0.02)
  • Comprehensive income amounted to - 3,440 thousand (-1,757)
  • FDA approved Oasmia’s production facility in Uppsala
  • Increased financing by extension of the MSEK 105 loan from Nexttobe AB and a new MSEK 40 bank loan.

    

THE PERIOD May 1, 2013 – January 31, 2014

  • Consolidated Net sales amounted to 5 thousand (0)
  • Operating income amounted to -7,105 thousand (-5,162)
  • Net income after tax amounted to -7,610 thousand (-5,587)
  • Earnings per share amounted to -0.09 (-0.09)
  • Comprehensive income amounted to -7,610 thousand (-5,587)
  • Oasmia initiated a clinical program for Paclical for treatment of breast cancer
     
  • Oasmia initiated pre-clinical studies with OAS-19, the first pharmaceutical project with a combination of two active cytostatics in one infusion

    

EVENTS AFTER CLOSING DAY

  • Oasmia is granted conditional FDA approval for Paccal Vet

 

 

[1]The numbers in brackets concern results from the corresponding period of the previous year